The use of non-insulin anti-diabetic agents to improve glycemia without hypoglycemia in the hospital setting

Focus on incretins

Stanley Schwartz, Ralph A Defronzo

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Patients with hyperglycemia in hospital have increased adverse outcomes compared with patients with normoglycemia, and the pathophysiological causes seem relatively well understood. Thus, a rationale for excellent glycemic control exists. Benefits of control with intensive insulin regimes are highly likely based on multiple published studies. However, hypoglycemia frequency increases and adverse outcomes of hypoglycemia accrue. This has resulted in a 'push' for therapeutic nihilism, accepting higher glycemic levels to avoid hypoglycemia. One would ideally prefer to optimize glycemia, treating hyperglycemia while minimizing or avoiding hypoglycemia. Thus, one would welcome therapies and processes of care to optimize this benefit/ risk ratio. We review the logic and early studies that suggest that incretin therapy use in-hospital can achieve this ideal. We strongly urge randomized prospective controlled studies to test our proposal and we offer a process of care to facilitate this research and their use in our hospitalized patients.

Original languageEnglish (US)
Article number467
JournalCurrent Diabetes Reports
Volume14
Issue number3
DOIs
StatePublished - 2014

Fingerprint

Incretins
Hypoglycemia
Hyperglycemia
Therapeutics
Odds Ratio
Prospective Studies
Insulin
Research

Keywords

  • DPP-4 inhibitors
  • GLP-1 receptor agonists
  • Glycemia
  • Hypoglycemia
  • In-hospital diabetes control
  • Incretins
  • Intensive insulin therapy
  • Noninsulin anti-diabetic agents

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

@article{25faa4bf4bef4f21b55d4a6186ec1033,
title = "The use of non-insulin anti-diabetic agents to improve glycemia without hypoglycemia in the hospital setting: Focus on incretins",
abstract = "Patients with hyperglycemia in hospital have increased adverse outcomes compared with patients with normoglycemia, and the pathophysiological causes seem relatively well understood. Thus, a rationale for excellent glycemic control exists. Benefits of control with intensive insulin regimes are highly likely based on multiple published studies. However, hypoglycemia frequency increases and adverse outcomes of hypoglycemia accrue. This has resulted in a 'push' for therapeutic nihilism, accepting higher glycemic levels to avoid hypoglycemia. One would ideally prefer to optimize glycemia, treating hyperglycemia while minimizing or avoiding hypoglycemia. Thus, one would welcome therapies and processes of care to optimize this benefit/ risk ratio. We review the logic and early studies that suggest that incretin therapy use in-hospital can achieve this ideal. We strongly urge randomized prospective controlled studies to test our proposal and we offer a process of care to facilitate this research and their use in our hospitalized patients.",
keywords = "DPP-4 inhibitors, GLP-1 receptor agonists, Glycemia, Hypoglycemia, In-hospital diabetes control, Incretins, Intensive insulin therapy, Noninsulin anti-diabetic agents",
author = "Stanley Schwartz and Defronzo, {Ralph A}",
year = "2014",
doi = "10.1007/s11892-013-0466-9",
language = "English (US)",
volume = "14",
journal = "Current Diabetes Reports",
issn = "1534-4827",
publisher = "Current Medicine Group",
number = "3",

}

TY - JOUR

T1 - The use of non-insulin anti-diabetic agents to improve glycemia without hypoglycemia in the hospital setting

T2 - Focus on incretins

AU - Schwartz, Stanley

AU - Defronzo, Ralph A

PY - 2014

Y1 - 2014

N2 - Patients with hyperglycemia in hospital have increased adverse outcomes compared with patients with normoglycemia, and the pathophysiological causes seem relatively well understood. Thus, a rationale for excellent glycemic control exists. Benefits of control with intensive insulin regimes are highly likely based on multiple published studies. However, hypoglycemia frequency increases and adverse outcomes of hypoglycemia accrue. This has resulted in a 'push' for therapeutic nihilism, accepting higher glycemic levels to avoid hypoglycemia. One would ideally prefer to optimize glycemia, treating hyperglycemia while minimizing or avoiding hypoglycemia. Thus, one would welcome therapies and processes of care to optimize this benefit/ risk ratio. We review the logic and early studies that suggest that incretin therapy use in-hospital can achieve this ideal. We strongly urge randomized prospective controlled studies to test our proposal and we offer a process of care to facilitate this research and their use in our hospitalized patients.

AB - Patients with hyperglycemia in hospital have increased adverse outcomes compared with patients with normoglycemia, and the pathophysiological causes seem relatively well understood. Thus, a rationale for excellent glycemic control exists. Benefits of control with intensive insulin regimes are highly likely based on multiple published studies. However, hypoglycemia frequency increases and adverse outcomes of hypoglycemia accrue. This has resulted in a 'push' for therapeutic nihilism, accepting higher glycemic levels to avoid hypoglycemia. One would ideally prefer to optimize glycemia, treating hyperglycemia while minimizing or avoiding hypoglycemia. Thus, one would welcome therapies and processes of care to optimize this benefit/ risk ratio. We review the logic and early studies that suggest that incretin therapy use in-hospital can achieve this ideal. We strongly urge randomized prospective controlled studies to test our proposal and we offer a process of care to facilitate this research and their use in our hospitalized patients.

KW - DPP-4 inhibitors

KW - GLP-1 receptor agonists

KW - Glycemia

KW - Hypoglycemia

KW - In-hospital diabetes control

KW - Incretins

KW - Intensive insulin therapy

KW - Noninsulin anti-diabetic agents

UR - http://www.scopus.com/inward/record.url?scp=84893200678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893200678&partnerID=8YFLogxK

U2 - 10.1007/s11892-013-0466-9

DO - 10.1007/s11892-013-0466-9

M3 - Article

VL - 14

JO - Current Diabetes Reports

JF - Current Diabetes Reports

SN - 1534-4827

IS - 3

M1 - 467

ER -